Phathom Pharmaceuticals (PHAT) News Today $4.77 +0.14 (+3.02%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$4.39 -0.38 (-8.05%) As of 05:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Phathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $28.00 target price on shares of Phathom Pharmaceuticals in a research report on Wednesday.April 11, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells $16,734.90 in StockPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) CFO Molly Henderson sold 3,678 shares of the firm's stock in a transaction dated Monday, April 7th. The stock was sold at an average price of $4.55, for a total transaction of $16,734.90. Following the completion of the transaction, the chief financial officer now directly owns 89,868 shares in the company, valued at approximately $408,899.40. This represents a 3.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.April 10, 2025 | marketbeat.comInsider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 3,678 Shares of StockApril 9, 2025 | insidertrades.comTrexquant Investment LP Makes New $3.08 Million Investment in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Trexquant Investment LP acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 378,637 shares of the company's stock, valued at approximately $3,075,000. TrexquanApril 8, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Average Price Target from AnalystsApril 7, 2025 | americanbankingnews.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Buy" by BrokeragesPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) has been assigned an average recommendation of "Buy" from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have givenApril 6, 2025 | marketbeat.com‘Saturday Night Live’ cast member breaks silence on health issueApril 5, 2025 | msn.comGuggenheim Reiterates "Buy" Rating for Phathom Pharmaceuticals (NASDAQ:PHAT)Guggenheim reiterated a "buy" rating on shares of Phathom Pharmaceuticals in a research report on Wednesday.April 4, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $28.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday.April 4, 2025 | marketbeat.comPhathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade)April 3, 2025 | seekingalpha.comPhathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 3, 2025 | globenewswire.comNeedham Remains a Buy on Phathom Pharmaceuticals (PHAT)April 2, 2025 | markets.businessinsider.comExclusive: How SNL Legend Kenan Thompson’s Disease Gave Him This ‘Light Bulb Moment’ as a Girl DadApril 2, 2025 | msn.comKenan Thompson Reveals How He’ll Know It’s Time to Leave ‘SNL’ After More Than 20 Years (Exclusive)April 2, 2025 | msn.comPhathom Pharmaceuticals appoints Basta as President, CEOApril 2, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Stock Falls on CEO SwitchApril 2, 2025 | marketwatch.comPhathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comPhathom Pharmaceuticals Names Basta President, CEO as Curran ResignsApril 1, 2025 | marketwatch.comPhathom Pharmaceuticals Announces Leadership SuccessionApril 1, 2025 | globenewswire.comPhathom Pharmaceuticals partners with Kenan Thompson for GERD awarenessMarch 31, 2025 | markets.businessinsider.comActor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)March 31, 2025 | globenewswire.comRaymond James Financial Inc. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Raymond James Financial Inc. acquired a new position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 455,837 shares of the company's sMarch 28, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $2.87 Million Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Charles Schwab Investment Management Inc. raised its stake in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 20.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 353,038 shares of the comMarch 28, 2025 | marketbeat.comSimplify Asset Management Inc. Grows Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)Simplify Asset Management Inc. lifted its position in shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 581,9March 24, 2025 | marketbeat.comPhathom Pharmaceuticals price target lowered to $13 from $17 at JefferiesMarch 20, 2025 | markets.businessinsider.comPhathom Pharmaceuticals director buys $44.2K shares of common stockMarch 17, 2025 | markets.businessinsider.comThe Goldman Sachs Group Issues Pessimistic Forecast for Phathom Pharmaceuticals (NASDAQ:PHAT) Stock PriceThe Goldman Sachs Group cut their price objective on shares of Phathom Pharmaceuticals from $18.00 to $12.00 and set a "neutral" rating for the company in a research report on Monday.March 11, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from AnalystsShares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT - Get Free Report) have earned a consensus rating of "Buy" from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and oMarch 11, 2025 | marketbeat.comPhathom Pharmaceuticals’ Earnings Call: Growth and ChallengesMarch 10, 2025 | tipranks.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comPhathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call TranscriptMarch 9, 2025 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a report on Friday.March 8, 2025 | marketbeat.comPhathom Pharmaceuticals price target lowered to $12 from $18 at Goldman SachsMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Full Year 2024 Earnings: Beats ExpectationsMarch 7, 2025 | uk.finance.yahoo.comPhathom Pharmaceuticals price target lowered to $18 from $28 at GuggenheimMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals price target lowered to $19 from $27 at Craig-HallumMarch 7, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...March 7, 2025 | finance.yahoo.comPhathom Pharmaceuticals' (PHAT) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Thursday.March 7, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Beats Expectations By $0.41 EPSPhathom Pharmaceuticals (NASDAQ:PHAT - Get Free Report) announced its earnings results on Thursday. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.41.March 7, 2025 | marketbeat.comPhathom Pharmaceuticals reports Q4 EPS ($1.05), consensus ($1.08)March 6, 2025 | markets.businessinsider.comPhathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 6, 2025 | globenewswire.comPhathom Pharmaceuticals (PHAT) Projected to Post Quarterly Earnings on ThursdayPhathom Pharmaceuticals (NASDAQ:PHAT) will be releasing earnings before the market opens on Thursday, March 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=669349)February 27, 2025 | marketbeat.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Rating Upgraded by Cantor FitzgeraldCantor Fitzgerald raised Phathom Pharmaceuticals to a "strong-buy" rating in a report on Tuesday.February 26, 2025 | marketbeat.com2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%February 25, 2025 | msn.comPhathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025February 24, 2025 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Now Covered by Cantor FitzgeraldCantor Fitzgerald began coverage on Phathom Pharmaceuticals in a research report on Friday. They issued an "overweight" rating and a $23.00 price objective for the company.February 15, 2025 | marketbeat.comPhathom spikes as Cantor Fitzgerald bullish on IP claimsFebruary 14, 2025 | msn.comPhathom Pharmaceuticals initiated with an Overweight at Cantor FitzgeraldFebruary 14, 2025 | markets.businessinsider.comPhathom Pharmaceuticals initiated at Cantor Fitzgerald on ‘significant’ upsideFebruary 14, 2025 | markets.businessinsider.comPhathom Pharmaceuticals (PHAT) Gets a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.com Remove Ads Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAT Media Mentions By Week PHAT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHAT News Sentiment▼0.970.79▲Average Medical News Sentiment PHAT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHAT Articles This Week▼53▲PHAT Articles Average Week Remove Ads Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ocular Therapeutix News Calliditas Therapeutics AB (publ) News Evotec News Amphastar Pharmaceuticals News Adaptive Biotechnologies News Iovance Biotherapeutics News Ardelyx News Structure Therapeutics News Aurinia Pharmaceuticals News Syndax Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHAT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
